Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.

Oppenheimer Holdings, Inc. reaffirmed their outperform rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report released on Tuesday morning. The brokerage currently has a $41.00 target price on the stock.

A number of other brokerages have also weighed in on TEVA. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a sell rating to a hold rating and set a $32.27 target price on the stock in a research report on Wednesday, June 28th. Royal Bank Of Canada restated an outperform rating and issued a $38.00 target price (down previously from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, May 15th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a sell rating to a hold rating in a research report on Monday, April 17th. Wells Fargo & Company restated a market perform rating on shares of Teva Pharmaceutical Industries Limited in a research report on Saturday, April 29th. Finally, Mizuho upgraded shares of Teva Pharmaceutical Industries Limited from a neutral rating to a buy rating and raised their target price for the company from $25.00 to $30.00 in a research report on Thursday, June 15th. Sixteen research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has an average rating of Hold and an average target price of $42.78.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.37% on Tuesday, reaching $32.55. The company’s stock had a trading volume of 2,532,466 shares. The firm has a market cap of $33.07 billion, a P/E ratio of 417.31 and a beta of 0.47. Teva Pharmaceutical Industries Limited has a 12 month low of $27.59 and a 12 month high of $55.79. The firm’s 50 day moving average is $31.34 and its 200-day moving average is $32.48.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.06. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The firm had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.69 billion. During the same quarter last year, the business posted $1.20 earnings per share. The company’s quarterly revenue was up 17.0% on a year-over-year basis. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://sportsperspectives.com/2017/07/21/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.

The business also recently declared a quarterly dividend, which was paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 4.19%. The ex-dividend date of this dividend was Thursday, June 1st. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently 5,802.90%.

Large investors have recently bought and sold shares of the stock. Cribstone Capital Management LLC increased its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the period. Bronfman E.L. Rothschild L.P. increased its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the period. FNY Managed Accounts LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter valued at $123,000. Sterling Investment Advisors Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the period. Finally, Financial Architects Inc increased its stake in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares during the period. 56.26% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply